Generic Firms Fear 'New Lifecycle Management Tool' From FDA Pill Size Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.